Sadiq Altamimi, MD
Clinical Neurophysiology · Pomona, CANPI 1639381619
Payments from drug & device makers
Across 1,674 payments — averaging $207.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$274K
- Argenx US, Inc.$45K
- AbbVie$5K
- UCB, Inc.$3K
- AstraZeneca$2K
- Biogen$2K
- plus $17K from 54 others
What the payments were for
- Speaking & faculty fees$440%
- Food & beverage$29,74399%
- Education$1450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANZYGA$760
- INBRIJA$188
- Austedo XR$161
- UPLIZNA$125
- Mavenclad$125
How this compares
$347,798 in reported general payments places this provider in the 80th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 371 | $3,172,359 |
| UltomirisRavulizumab-Cwvz | 44 | $2,014,135 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 188 | $1,313,821 |
| VyvgartEfgartigimod Alfa-Fcab | 22 | $1,262,206 |
| SolirisEculizumab | 18 | $860,409 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 73 | $535,850 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 31 | $382,317 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $268,987 |
| AustedoDeutetrabenazine | 18 | $252,287 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $231,038 |
| BotoxOnabotulinumtoxina | 124 | $157,083 |
| NuplazidPimavanserin Tartrate | 21 | $136,780 |
| TysabriNatalizumab | 12 | $100,004 |
| CopaxoneGlatiramer Acetate | 11 | $59,459 |
| RexultiBrexpiprazole | 24 | $39,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga, Lyrica | $1,072 | $3,422,047395 claims |
| AstraZenecaUltomiris, Soliris | $2,008 | $2,874,54462 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $313 | $1,313,821188 claims |
| Argenx US, Inc.Vyvgart | $44,769 | $1,262,20622 claims |
| CSL BehringPrivigen | $200 | $535,85073 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $1,091 | $311,74629 claims |
| Grifols USA, LLCGamunex-C | $78 | $268,98717 claims |
| AbbVieBotox, Qulipta, Namzaric | $4,870 | $193,403159 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,498 | $136,78021 claims |
| BiogenTysabri | $1,738 | $100,00412 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $460 | $39,05724 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $506 | $33,16517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 clinical neurophysiology providers in California.
Other clinical neurophysiology in Pomona
- Puja MathurPomona$6K
- Said BeydounLos Angeles$2.5M
- Christopher LockStanford$1.3M
- Mitchell MiglisStanford$826K
- Lucas KippPalo Alto$791K
- Srikanth MuppidiStanford$761K
- Helen Bronte-StewartStanford$672K
- Laurice YangStanford$477K
- Kathleen PostonStanford$458K
- Dominic FerreySan Diego$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.